A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo

Zhibo An, Jason J. Winnick, Ben Farmer, Doss Neal, Margaret Lautz, Jose M. Irimia, Peter Roach, Alan D. Cherrington

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE - We previously showed that elevating hepatic nitric oxide (NO) levels reduced net hepatic glucose uptake (NHGU) in the presence of portal glucose delivery, hyperglycemia, and hyperinsulinemia. The aim of the present study was to determine the role of a downstream signal, soluble guanylate cyclase (sGC), in the regulation of NHGU by NO. RESEARCH DESIGN AND METHODS - Studies were performed on 42-h-fasted conscious dogs fitted with vascular catheters. At 0 min, somatostatin was given peripherally along with 4x basal insulin and basal glucagon intraportally. Glucose was delivered at a variable rate via a leg vein to double the blood glucose level and hepatic glucose load throughout the study. From 90 to 270 min, an intraportal infusion of the sGC inhibitor 1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one (ODQ) was given in -sGC (n = 10) and -sGC/+NO (n = 6), whereas saline was given in saline infusion (SAL) (n = 10). The -sGC/+NO group also received intraportal SIN-1 (NO donor) to elevate hepatic NO from 180 to 270 min. RESULTS - In the presence of 4x basal insulin, basal glucagon, and hyperglycemia (2x basal), inhibition of sGC in the liver enhanced NHGU (mg/kg/min; 210-270 min) by ∼55% (2.9 ± 0.2 in SAL vs. 4.6 ± 0.5 in -sGC). Further elevating hepatic NO failed to reduce NHGU (4.5 ± 0.7 in -sGC/+NO). Net hepatic carbon retention (i.e., glycogen synthesis; mg glucose equivalents/kg/min) increased to 3.8 ± 0.2 in -sGC and 3.8 ± 0.4 in -sGC/+NO vs. 2.4 ± 0.2 in SAL (P < 0.05). CONCLUSIONS - NO regulates liver glucose uptake through a sGC-dependent pathway. The latter could be a target for pharmacologic intervention to increase meal-associated hepatic glucose uptake in individuals with type 2 diabetes.

Original languageEnglish
Pages (from-to)2999-3007
Number of pages9
JournalDiabetes
Volume59
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Nitric Oxide
Glucose
Liver
Glucagon
Hyperglycemia
Soluble Guanylyl Cyclase
Insulin
Vascular Access Devices
Nitric Oxide Donors
Hyperinsulinism
Somatostatin
Glycogen
Type 2 Diabetes Mellitus
Meals
Blood Glucose
Veins
Leg
Research Design
Carbon
Dogs

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

An, Z., Winnick, J. J., Farmer, B., Neal, D., Lautz, M., Irimia, J. M., ... Cherrington, A. D. (2010). A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo. Diabetes, 59(12), 2999-3007. https://doi.org/10.2337/db10-0138

A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo. / An, Zhibo; Winnick, Jason J.; Farmer, Ben; Neal, Doss; Lautz, Margaret; Irimia, Jose M.; Roach, Peter; Cherrington, Alan D.

In: Diabetes, Vol. 59, No. 12, 12.2010, p. 2999-3007.

Research output: Contribution to journalArticle

An, Z, Winnick, JJ, Farmer, B, Neal, D, Lautz, M, Irimia, JM, Roach, P & Cherrington, AD 2010, 'A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo', Diabetes, vol. 59, no. 12, pp. 2999-3007. https://doi.org/10.2337/db10-0138
An, Zhibo ; Winnick, Jason J. ; Farmer, Ben ; Neal, Doss ; Lautz, Margaret ; Irimia, Jose M. ; Roach, Peter ; Cherrington, Alan D. / A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo. In: Diabetes. 2010 ; Vol. 59, No. 12. pp. 2999-3007.
@article{716a3a9a802a4aa2afed68903773a23c,
title = "A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo",
abstract = "OBJECTIVE - We previously showed that elevating hepatic nitric oxide (NO) levels reduced net hepatic glucose uptake (NHGU) in the presence of portal glucose delivery, hyperglycemia, and hyperinsulinemia. The aim of the present study was to determine the role of a downstream signal, soluble guanylate cyclase (sGC), in the regulation of NHGU by NO. RESEARCH DESIGN AND METHODS - Studies were performed on 42-h-fasted conscious dogs fitted with vascular catheters. At 0 min, somatostatin was given peripherally along with 4x basal insulin and basal glucagon intraportally. Glucose was delivered at a variable rate via a leg vein to double the blood glucose level and hepatic glucose load throughout the study. From 90 to 270 min, an intraportal infusion of the sGC inhibitor 1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one (ODQ) was given in -sGC (n = 10) and -sGC/+NO (n = 6), whereas saline was given in saline infusion (SAL) (n = 10). The -sGC/+NO group also received intraportal SIN-1 (NO donor) to elevate hepatic NO from 180 to 270 min. RESULTS - In the presence of 4x basal insulin, basal glucagon, and hyperglycemia (2x basal), inhibition of sGC in the liver enhanced NHGU (mg/kg/min; 210-270 min) by ∼55{\%} (2.9 ± 0.2 in SAL vs. 4.6 ± 0.5 in -sGC). Further elevating hepatic NO failed to reduce NHGU (4.5 ± 0.7 in -sGC/+NO). Net hepatic carbon retention (i.e., glycogen synthesis; mg glucose equivalents/kg/min) increased to 3.8 ± 0.2 in -sGC and 3.8 ± 0.4 in -sGC/+NO vs. 2.4 ± 0.2 in SAL (P < 0.05). CONCLUSIONS - NO regulates liver glucose uptake through a sGC-dependent pathway. The latter could be a target for pharmacologic intervention to increase meal-associated hepatic glucose uptake in individuals with type 2 diabetes.",
author = "Zhibo An and Winnick, {Jason J.} and Ben Farmer and Doss Neal and Margaret Lautz and Irimia, {Jose M.} and Peter Roach and Cherrington, {Alan D.}",
year = "2010",
month = "12",
doi = "10.2337/db10-0138",
language = "English",
volume = "59",
pages = "2999--3007",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo

AU - An, Zhibo

AU - Winnick, Jason J.

AU - Farmer, Ben

AU - Neal, Doss

AU - Lautz, Margaret

AU - Irimia, Jose M.

AU - Roach, Peter

AU - Cherrington, Alan D.

PY - 2010/12

Y1 - 2010/12

N2 - OBJECTIVE - We previously showed that elevating hepatic nitric oxide (NO) levels reduced net hepatic glucose uptake (NHGU) in the presence of portal glucose delivery, hyperglycemia, and hyperinsulinemia. The aim of the present study was to determine the role of a downstream signal, soluble guanylate cyclase (sGC), in the regulation of NHGU by NO. RESEARCH DESIGN AND METHODS - Studies were performed on 42-h-fasted conscious dogs fitted with vascular catheters. At 0 min, somatostatin was given peripherally along with 4x basal insulin and basal glucagon intraportally. Glucose was delivered at a variable rate via a leg vein to double the blood glucose level and hepatic glucose load throughout the study. From 90 to 270 min, an intraportal infusion of the sGC inhibitor 1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one (ODQ) was given in -sGC (n = 10) and -sGC/+NO (n = 6), whereas saline was given in saline infusion (SAL) (n = 10). The -sGC/+NO group also received intraportal SIN-1 (NO donor) to elevate hepatic NO from 180 to 270 min. RESULTS - In the presence of 4x basal insulin, basal glucagon, and hyperglycemia (2x basal), inhibition of sGC in the liver enhanced NHGU (mg/kg/min; 210-270 min) by ∼55% (2.9 ± 0.2 in SAL vs. 4.6 ± 0.5 in -sGC). Further elevating hepatic NO failed to reduce NHGU (4.5 ± 0.7 in -sGC/+NO). Net hepatic carbon retention (i.e., glycogen synthesis; mg glucose equivalents/kg/min) increased to 3.8 ± 0.2 in -sGC and 3.8 ± 0.4 in -sGC/+NO vs. 2.4 ± 0.2 in SAL (P < 0.05). CONCLUSIONS - NO regulates liver glucose uptake through a sGC-dependent pathway. The latter could be a target for pharmacologic intervention to increase meal-associated hepatic glucose uptake in individuals with type 2 diabetes.

AB - OBJECTIVE - We previously showed that elevating hepatic nitric oxide (NO) levels reduced net hepatic glucose uptake (NHGU) in the presence of portal glucose delivery, hyperglycemia, and hyperinsulinemia. The aim of the present study was to determine the role of a downstream signal, soluble guanylate cyclase (sGC), in the regulation of NHGU by NO. RESEARCH DESIGN AND METHODS - Studies were performed on 42-h-fasted conscious dogs fitted with vascular catheters. At 0 min, somatostatin was given peripherally along with 4x basal insulin and basal glucagon intraportally. Glucose was delivered at a variable rate via a leg vein to double the blood glucose level and hepatic glucose load throughout the study. From 90 to 270 min, an intraportal infusion of the sGC inhibitor 1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one (ODQ) was given in -sGC (n = 10) and -sGC/+NO (n = 6), whereas saline was given in saline infusion (SAL) (n = 10). The -sGC/+NO group also received intraportal SIN-1 (NO donor) to elevate hepatic NO from 180 to 270 min. RESULTS - In the presence of 4x basal insulin, basal glucagon, and hyperglycemia (2x basal), inhibition of sGC in the liver enhanced NHGU (mg/kg/min; 210-270 min) by ∼55% (2.9 ± 0.2 in SAL vs. 4.6 ± 0.5 in -sGC). Further elevating hepatic NO failed to reduce NHGU (4.5 ± 0.7 in -sGC/+NO). Net hepatic carbon retention (i.e., glycogen synthesis; mg glucose equivalents/kg/min) increased to 3.8 ± 0.2 in -sGC and 3.8 ± 0.4 in -sGC/+NO vs. 2.4 ± 0.2 in SAL (P < 0.05). CONCLUSIONS - NO regulates liver glucose uptake through a sGC-dependent pathway. The latter could be a target for pharmacologic intervention to increase meal-associated hepatic glucose uptake in individuals with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=78650073368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650073368&partnerID=8YFLogxK

U2 - 10.2337/db10-0138

DO - 10.2337/db10-0138

M3 - Article

C2 - 20823104

AN - SCOPUS:78650073368

VL - 59

SP - 2999

EP - 3007

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -